Drug Discovery World

AUGUST 30, 2022

The Phacilitate Advanced Therapies Europe 2022 conference will take place from 30 August to 1 September at the Royal Lancaster in London, UK. The conference is the European twin to Phacilitate Advanced Therapies Week, an event held in January in Florida, US. The event is tailored to a European audience looking to commercialise ATMPs globally, as well as a global audience looking to understand and expand into the European market.

Therapies 246

Therapies Hospitals Clinical Trials Clinical Development 246

Drug Discovery Today

AUGUST 31, 2022

In the lead up to the inaugural launch of Connect In Pharma, co-founder Wilfried Phipps provides insight into what visitors can expect at this new annual event designed to help shape the future of pharmaceutical packaging and manufacturing projects

Packaging 113

Packaging Pharmaceuticals 113

Antidote

AUGUST 29, 2022

In the world of medical research, experts are constantly looking for new drugs, treatments, and therapies for a variety of conditions — but the process of getting these treatments approved is only possible if they are tested through clinical trials.

Clinical Trials 98

Clinical Trials Trials Therapies Treatment 98

Drug Patent Watch

SEPTEMBER 2, 2022

Annual Drug Patent Expirations for FINTEPLA Fintepla is a drug marketed by Zogenix Inc and is included in one NDA. It is available from one supplier. There are eleven patents…. The post New patent for Zogenix Inc drug FINTEPLA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Clinical Trials

Drug Discovery World

SEPTEMBER 2, 2022

A recent study by the University of Colorado School of Medicine shows that diabetes drug metformin is effective for preventing severe illness from Covid-19. The CU School of Medicine was part of a multi-site clinical trial into the effectiveness of metformin, ivermectin and fluvoxamine in non-hospitalised adults with Covid-19. . The study, which launched in January 2021, included those who were vaccinated and those who were not, as well as people who were pregnant.

Drugs 243

Drugs Clinical Trials Trials Vaccine 243

EG Life Sciences

SEPTEMBER 1, 2022

Introduction As we shared in Part 1 , the future of Pharma and Biotech is possible because of new tools and technologies, along with all clinical discoveries and relevant data that has accumulated throughout the years. In that blog, we learned about the technology drivers behind the Biotech processes and the collaborative strategies accelerating changes, facilitating dynamic response and the globalization of markets.

Marketing 52

Marketing Science 52

Drug Patent Watch

SEPTEMBER 2, 2022

Annual Drug Patent Expirations for EPIDIOLEX Epidiolex is a drug marketed by Gw Res Ltd and is included in one NDA. It is available from one supplier. There are twenty-two…. The post New patent for Gw Res drug EPIDIOLEX appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Discovery World

SEPTEMBER 2, 2022

Scientists from Tokyo University of Science have shed light on how various molecules are recruited in endocytosis, a cellular process of bringing in different types of materials from the outside. The results suggest key regulatory functions of the yeast Eps15-like protein Pan1p. The findings provide important insights into the process, which is central to disease prevention.

Cell Biology 130

Cell Biology Science Regulations Therapies 130

Advarra

AUGUST 31, 2022

In response to a growing demand for faster, approved, and cost-effective medical devices for chronic diseases, medical device manufacturers and emerging biotech companies are facing increasingly complex pathways to successfully bring their innovative ideas to the market. If a new medical device, software as a medical device (SaMD), or in vitro diagnostic (IVD) is poised to successfully make it through the development process to commercialization, sponsors must consider a trifecta of interconnect

Research 52

Research Regulations Clinical Trials Trials 52

Pharma Manufacturing

AUGUST 29, 2022

Ethan Smith, general manager, Life Sciences at Nuvolo discusses how furthering pharma’s digitalization journey can help the industry reap big benefits in quality and manufacturing.

Science 40

Science 40

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Clinical Trials

Drug Patent Watch

SEPTEMBER 2, 2022

Annual Drug Patent Expirations for MYFEMBREE Myfembree is a drug marketed by Myovant Sciences and is included in one NDA. There are four patents protecting this drug. This drug has…. The post New patent for Myovant Sciences drug MYFEMBREE appeared first on DrugPatentWatch - Make Better Decisions.

Science 52

Science Drugs Marketing 52

Drug Discovery World

SEPTEMBER 2, 2022

Investment from Takeda ventures will fund the development of Zelluna Immunotherapy’s allogeneic T Cell Receptor Natural Killer (TCR-NK) cells for the treatment of cancer. The funds will enable the advancement of a lead TCR-NK product through manufacturing to Clinical Trial Application (CTA) / Investigational New Drug Application (IND) readiness and, continue the advancement of Zelluna’s platform with additional programmes reaching the preclinical stage.

Treatment 130

Treatment Clinical Trials Therapies Production 130

Advarra

AUGUST 31, 2022

Institutional biosafety committees (IBCs) frequently receive questions about the proper methodology for preparing a syringe for transport from a drug room or pharmacy to the clinic where the injection will be administered. This article explores tools and techniques to safely mitigate occupational exposure risks when preparing a syringe for transport to the clinic.

Production 52

Production Engineering Pharmacy Virus 52

Pharma Manufacturing

SEPTEMBER 1, 2022

As patent barriers protecting the world's best-selling drug topple, biosimilars rush in

Biosimilars 40

Biosimilars Drugs 40

Advertisement

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

Clinical Trials

Drug Patent Watch

AUGUST 30, 2022

Annual Drug Patent Expirations for ABILIFY+MAINTENA+KIT Abilify Maintena Kit is a drug marketed by Otsuka Pharm Co Ltd and is included in one NDA. It is available from one supplier.…. The post New patent for Otsuka Pharm drug ABILIFY MAINTENA KIT appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Discovery World

SEPTEMBER 2, 2022

The Tech Theatre, supported by DDW, at ELRIG Drug Discovery 2022 will feature a series of seminars focused on automation and technology for drug discovery. . Raj Patey, Business Development Director, MyGreenLabs, will be discussing The Sustainable Lab: Building a Global Culture of Sustainability in Science. . Patey spends much of his time working with lab suppliers to communicate their product sustainability to lab users and to reduce the environmental impact of the lab supply chain.

Biosimilars 130

Biosimilars Drugs Science Production 130

LifeSciVC

AUGUST 30, 2022

By Peter Smith, co-founder and CEO, Remix Therapeutics, as part of the From The Trenches feature of LifeSciVC One of the joys of starting a company is the ability to pro-actively define the early corporate culture and encourage its evolution over time. When I think about what culture means and how to define it, it’s quickly apparent that what I think doesn’t matter.

Science 52

Science Bioinformatics Disease 52

Drug & Device Law

AUGUST 30, 2022

Today’s post is actually about a medical malpractice case. But it involves the interplay between an FDA “Safety Communication” and punitive damages, so we thought it was worth looking at. In Rivera v. Valley Hospital, Inc. , 2022 WL 3650726 (NJ Aug. 25, 2022), plaintiff is the representative of the estate of a woman who passed away from leiomyosarcoma, a rare uterine cancer.

FDA 59

FDA Hospitals Doctors Treatment 59

Drug Patent Watch

AUGUST 29, 2022

Annual Drug Patent Expirations for AMITIZA Amitiza is a drug marketed by Sucampo Pharma Llc and is included in one NDA. It is available from three suppliers. There are nine…. The post New patent expiration for Sucampo Pharma drug AMITIZA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Discovery World

SEPTEMBER 2, 2022

Charles River Laboratories has added five new Charles River Accelerator and Development Lab (CRADL) locations in California and Washington. . CRADL provides flexible, turnkey vivarium rental space supported by Charles River’s technical and veterinary support expertise in key biohubs. This allows clients to start new projects, accelerating the early stage of research.

Laboratories 130

Laboratories Clinical Development Drug Research Drugs 130

Drug Discovery World

SEPTEMBER 1, 2022

Scottish scientists are teaming up with researchers from Zambia to find new ways to diagnose and treat a condition which affects millions in Sub-Saharan Africa. . Ms Kanekwa Zyambo, from the University of Zambia, is spending two weeks at the Scottish Universities Environmental Research Centre in East Kilbride to master new technology to help understand environmental enteropathy (EE).

Research 130

Research Nurses Doctors Vaccine 130

Drug Discovery World

SEPTEMBER 1, 2022

Individuals with an autoimmune disorder have a substantially higher risk of developing cardiovascular disease, a large epidemiological study has revealed. . The research – led by KU Leuven in collaboration with colleagues in the UK, including the University of Glasgow, and published in The Lancet – shows for the first time that cardiovascular risks affect autoimmune disorders as a group of diseases, with implications across a broad range of cardiovascular outcomes. .

Disease 130

Disease Research Treatment Drugs 130

Drug Discovery World

SEPTEMBER 1, 2022

Bio-Rad Laboratories has introduced a range of type 1 antibodies that inhibit the binding of evolocumab (Repatha) to its target, human proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that has been shown to play a key role in the regulation of cholesterol levels. . These sequence-defined, recombinant antibodies are suitable for developing highly selective and sensitive pharmacokinetic (PK) and anti-drug antibody (ADA) assays for evolocumab and its biosimilars.

Drug Development 130

Drug Development Biosimilars Pharmacokinetics Drugs 130

Drug Discovery World

AUGUST 31, 2022

The European Commission (EC) has approved orphan drug Scemblix (asciminib), providing a new treatment option for patients who are intolerant or resistant to tyrosine kinase inhibitors (TKIs). It is approved to treat adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase who have been previously treated with two or more TKI therapies.

Therapies 130

Therapies Hospitals Treatment Trials 130

Drug Discovery World

AUGUST 31, 2022

A study led by LSU Health New Orleans cancer researchers describes a novel therapeutic strategy to overcome tumour-induced immunosuppression. For the first time, the research team identified a critical immunosuppressive pathway and a promising approach to intervene, protecting the ability of T-cells to attack cancer cells. Results are published in Frontiers in Immunology , available here.

Research 130

Research Drugs 130

Drug Discovery World

AUGUST 31, 2022

A group of latent stem cells could be the key to developing new therapeutic approaches to treat brain and spinal cord injuries, research shows. Scientists at the Francis Crick Institute identified a group of latent stem cells in mice which respond to injury in the central nervous system. If the same group is found in humans, the researchers believe it could lead to new therapeutic approaches to treat injuries of the brain and spinal cord.

Laboratories 130

Laboratories Research Therapies Drugs 130

Drug Discovery World

AUGUST 31, 2022

Biotechnology company Moderna has filed a patent infringement lawsuit against Pfizer and BioNTech in relation to the use of its messenger RNA (mRNA) technology and Pfizer and BioNTech’s Covid-19 Comirnaty vaccine. The lawsuits, which were made in the United States and Germany, state that Pfizer and BioNTech’s Covid-19 vaccine Comirnaty infringes Moderna’s patents for its mRNA technology filed between 2010 and 2016.

Vaccine 130

Vaccine RNA Licensing Licensing 130

Drug Discovery World

AUGUST 31, 2022

A new therapeutic approach for triple negative breast cancer using nitric oxide is being explored by researchers at the medical research centre CÚRAM. Amir Abdo Alsharabasy, a CÚRAM doctoral candidate working in the laboratory of Professor Abhay Pandit, is working on the design of nitric oxide scavengers to form a new treatment approach for this aggressive form of breast cancer.

Treatment 130

Treatment Clinical Trials Doctors Laboratories 130

Drug Discovery World

AUGUST 31, 2022

The amount of SARS-CoV-2 antibodies in the blood of patients hospitalised with Covid-19 could be used to predict illness severity and other clinical outcomes. . A new study, published in the Annals of Internal Medicine , shows that higher levels of viral antigen in the blood, which could indicate ongoing SARS-CoV-2 replication, correlated with more severe disease. .

Hospitals 130

Hospitals Trials Virus International 130

Drug Discovery World

AUGUST 30, 2022

A new study has found that the antiviral tecovirimat (TPOXX) appears to be safe and effective for the treatment of monkeypox symptoms and skin lesions. This University of California Davis Health (UC Davis Health) study is one of the earliest studies to assess and report the outcomes of treating patients with monkeypox with this antiviral. TPOXX is an FDA-approved antiviral drug for the treatment of smallpox.

Therapies 130

Therapies FDA Approval Vaccine Treatment 130

Drug Discovery World

AUGUST 29, 2022

Supported by DDW, the Tech Theatre at ELRIG Drug Discovery 2022 will feature a series of seminars focused on automation and technology for drug discovery. . Dr?Yahya Anvar, Head of Data Science Okra.AI will be discussing The Role of AI and Automation in Personalised Medicine: How can AI Help in The Post Drug Discovery Process.?? . Dr?Yahya Anvar, Head of Data Science Okra.AI.

Bioinformatics 130

Bioinformatics Biosimilars Drugs Science 130

Drug Patent Watch

SEPTEMBER 2, 2022

Lisdexamfetamine dimesylate is the generic ingredient in one branded drug marketed by Takeda Pharms Usa and is included in two NDAs. There are nineteen patents protecting this compound. Drug patent…. The post New tentative approval for Amneal Pharms drug lisdexamfetamine dimesylate appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 40

Drugs Marketing 40

Drug Patent Watch

AUGUST 31, 2022

Lisdexamfetamine dimesylate is the generic ingredient in one branded drug marketed by Takeda Pharms Usa and is included in two NDAs. There are nineteen patents protecting this compound. Drug patent…. The post New tentative approval for Amneal Pharms drug lisdexamfetamine dimesylate appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 40

Drugs Marketing 40

Drug Patent Watch

AUGUST 30, 2022

Lisdexamfetamine dimesylate is the generic ingredient in one branded drug marketed by Takeda Pharms Usa and is included in two NDAs. There are nineteen patents protecting this compound. Drug patent…. The post New tentative approval for Amneal Pharms drug lisdexamfetamine dimesylate appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 40

Drugs Marketing 40